ArticleCancer gene therapy2003
RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines.
Article in Cancer gene therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 116 citations in OpenAlex.
- Exploring the Potential of siRNA Delivery in Acute Myeloid Leukemia for Therapeutic Silencing.Nanomaterials (Basel, Switzerland) · 2023Article
- Nucleic Acids and Their Analogues for Biomedical Applications.Biosensors · 2022Review
- Article
- Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles for the treatment of acute myeloid leukemia.Cancer gene therapy · 2020Article
- Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy.OncoTargets and therapy · 2018Review
- Nano-based delivery of RNAi in cancer therapy.Molecular cancer · 2017Review
- Knockdown of Gli1 by small-interfering RNA enhances the effects of BCNU on the proliferation and apoptosis of glioma U251 cells.International journal of clinical and experimental pathology · 2015Article
- Differential gene expression profiles of PPP2R5C-siRNA-treated malignant T cells.DNA and cell biology · 2013Article
- Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation.Journal of hematology & oncology · 2013Article
- The effect of Bcl-2 siRNA combined with miR-15a oligonucleotides on the growth of Raji cells.Medical oncology (Northwood, London, England) · 2013Article
- Combined transfection of Bcl-2 siRNA and miR-15a oligonucleotides enhanced methotrexate-induced apoptosis in Raji cells.Cancer biology & medicine · 2013Article
- Downregulation of BCL11A by siRNA induces apoptosis in B lymphoma cell lines.Biomedical reports · 2013Article
- Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethylenimines.PloS one · 2012Article
- Silencing of HMGA1 expression by RNA interference suppresses growth of osteogenic sarcoma.Molecular and cellular biochemistry · 2011Article
- Personalized cancer approach: using RNA interference technology.World journal of surgery · 2011Review
- Fenoterol, a beta(2)-adrenoceptor agonist, inhibits LPS-induced membrane-bound CD14, TLR4/CD14 complex, and inflammatory cytokines production through beta-arrestin-2 in THP-1 cell line.Acta pharmacologica Sinica · 2009Article
- Therapeutic opportunities of small interfering RNA.Fundamental & clinical pharmacology · 2009Review
- c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro.Journal of neuro-oncology · 2009Article
- Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts.Cancer gene therapy · 2008Article
- Genetic variants contributing to daunorubicin-induced cytotoxicity.Cancer research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRNA interference (RNAi) is a cellular pathway of gene silencing in a sequence-specific manner at the messenger RNA level. The basic mechanism behind RNAi is the breaking of a double-stranded RNA (dsRNA) matching a specific gene sequence into short pieces called short interfering RNA, which trigger the degradation of mRNA that matches its sequence. In this study, we explored the effects of RNAi in reducing the target gene expression in human myeloid leukemia cell lines.
methodsFour myeloid leukemia cell lines (HL-60, U937, THP-1, and K562) were transfected with dsRNA duplexes corresponding to the endogenous c-raf and bcl-2 genes and the gene expression inhibition was assessed. The effect of RNAi on cell differentiation was studied; the apoptosis induction and the sensitization of the leukemia cell lines to etoposide and daunorubicin were quantified by flowcytometric methods.
resultsTransfection of the myeloid leukemia cell lines with dsRNA corresponding to c-raf and bcl-2 genes decreased the expression of Raf-1 and Bcl-2 proteins. RNAi for c-raf gene blocked the appearance of the monocytic differentiation induced by treatment with TPA. Combined RNAi for c-raf and bcl-2 induced apoptosis in HL-60, U937, and THP-1 cells and increased chemosensitivity to etoposide and daunorubicin.
conclusionsRNAi is a functional pathway in human myeloid leukemia cell lines and combined RNAi of c-raf and bcl-2 genes may represent a novel approach to leukemia, providing a means to overcome the resistance to chemotherapeutic agents and ultimately to augment the efficacy of chemotherapy in myeloid leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.